GILEAD & GENMAB
To Access Genmab’s (GEN) bispecific antibody technology, Gilead (GILD) signed a new agreement with Genmab. The King of HIV treatment objective is to use its exclusive license from Genmab to produce an HIV bispecific monoclonal antibody therapeutic.
Gilead is paying around $5 million in upfront payment and up to $277 million in milestones. Genmab will also be entitled to one-digit royalty of the rug’s sales in case an HIV drug would be approved and marketed
It is said that teams at the NIH, The Rockefeller University and Duke . . .
This content is for paid subscribers.
Today’s Highlights August 15, 2016